AutoGenomics withdraws IPO; Cordis gets OK for Exoseal;

> AutoGenomics, which makes molecular diagnostic machines, has withdrawn its regulatory filings for an initial public offering after a nearly three-year process, saying it chose not to offer itself on the open market at this time. Report

> Cordis has gotten the FDA's OK for the Exoseal vascular closure device. The device incorporates a number of new advances in technology and simplicity of design to provide precise and secure extravascular arterial closure. Cordis release

> St. Jude Medical has announced the Australian market launch of the Epiducer lead delivery system for neurostimulation therapy for the management of chronic pain. St. Jude release

> If you have a faulty heart valve and decide to get it replaced, a surgeon will implant an artificial one that has undergone rigorous examination by the FDA. But if you choose to repair your valve with an annuloplasty ring, there are no such guarantees, even though both devices are permanently stitched into the heart and considered life-sustaining, the Chicago Tribune notes. Story

> Israel's IceCure Medical says it plans to open its U.S. headquarters at the Cleveland Clinic-led Global Cardiovascular Innovation Center campus June 1. More

> Super Religare Laboratories has withdrawn its draft offer document filed with the Indian capital market regulator for an initial share sale, as the medical diagnostics chain operator needs to revise the document to reflect a new ownership pattern. News

And Finally... Engineers always are seeking ways to generate electricity from just about anything--from ocean waves and river currents to much smaller micro-generators that harvest ambient vibrations from automobiles crossing a bridge. Now Swiss researchers want to tap the human bloodstream. Using a tiny turbine installed in a blood vessel, researchers could generate the microwatts needed to keep implanted medical devices ticking. News

Suggested Articles

A decade-long study found that patients with early breast cancer may be spared radiation procedures that span the whole breast.

A cell therapy for Parkinson’s disease starts out simple, but quickly gets complicated with the potential for immune responses and cancer mutations.

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.